Lymph node ratio as an alternative to pN staging in node-positive breast cancer.

PURPOSE In the current pTNM classification system, nodal status of breast cancer is based on the number of involved lymph nodes and does not account for the total number of lymph nodes removed. In this study, we assessed the prognostic value of the lymph node ratio (LNR; ie, ratio of positive over excised lymph nodes) as compared with pN staging and determined its optimal cutoff points. PATIENTS AND METHODS From the Geneva Cancer Registry, we identified all women diagnosed with node-positive breast cancer between 1980 and 2004 (n = 1,829). The prognostic value of LNRs was calculated for values ranging from 0.05 to 0.95 by Cox regression analysis and validated by bootstrapping. Based on maximum likelihood, we identified cutoff points classifying women into low-, intermediate-, and high-risk LNR groups. RESULTS Optimal cutoff points classified patients into low- (< or = 0.20), intermediate- (> 0.20 and < or = 0.65), and high-risk (> 0.65) LNR groups, corresponding to 10-year disease-specific survival rates of 75%, 63%, and 40%, and adjusted mortality risks of 1 (reference), 1.78 (95% CI, 1.46 to 2.18), and 3.21 (95% CI, 2.54 to 4.06), respectively. In contrast to LNR risk categories, survival curves of pN2 and pN3 crossed after 15 years, and their adjusted mortality risks showed overlapping CIs: 2.07 (95% CI, 1.69 to 2.53) and 2.84 (95% CI, 2.23 to 3.61), respectively. CONCLUSION LNR predicts survival after breast cancer more accurately than pN classification and should be considered as an alternative to pN staging.

[1]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[2]  Valerii Fedorov,et al.  Consequences of dichotomization , 2009, Pharmaceutical statistics.

[3]  Vincent Vinh-Hung,et al.  Distribution statistique des ganglions lymphatiques axillaires envahis lors du cancer du sein , 2008 .

[4]  T. Kroll,et al.  Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Purushotham,et al.  A model for predicting non‐sentinel lymph node metastatic disease when the sentinel lymph node is positive , 2008, The British journal of surgery.

[6]  C. Divino,et al.  Prognostic significance of the number of lymph node metastases in esophageal cancer. , 2008, Journal of the American College of Surgeons.

[7]  V. Vinh-Hung,et al.  [Statistical distribution of involved axillary lymph nodes in breast cancer]. , 2008, Bulletin du cancer.

[8]  P. V. van Diest,et al.  Predictive Value of Tumor Load in Breast Cancer Sentinel Lymph Nodes for Second Echelon Lymph Node Metastases , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[9]  J. Chan,et al.  The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients , 2007, British Journal of Cancer.

[10]  C. Cox Predictors of Tumour Involvement in Remaining Axillary Lymph Nodes of Breast Cancer Patients With Positive Sentinel Lymph Node , 2007 .

[11]  G. Storme,et al.  The statistical distribution of involved axillary lymph nodes in breast cancer: A SEER population-based study , 2007 .

[12]  S. Akinaga,et al.  A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models , 2007, Breast Cancer Research and Treatment.

[13]  J. Haukoos,et al.  Evaluation of Three Scoring Systems Predicting Non Sentinel Node Metastasis in Breast Cancer Patients with a Positive Sentinel Node Biopsy , 2007, Annals of Surgical Oncology.

[14]  E. Yıldırım,et al.  Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients , 2007, World Journal of Surgery.

[15]  B. Kuru Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  Robert C. G. Martin,et al.  Prediction of sentinel lymph node-only disease in women with invasive breast cancer. , 2006, American journal of surgery.

[17]  M. Ridder,et al.  Prognostic value of the lymph node ratio in node positive colon cancer , 2006, Gut.

[18]  G. Vlastos,et al.  0469: Prognostic Importance of Nodal Involvement in Vulvar Carcinoma (Vc) , 2006, International Journal of Gynecologic Cancer.

[19]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Woodward,et al.  Prognostic value of nodal ratios in node-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Wood Generalized Additive Models: An Introduction with R , 2006 .

[22]  R. Abe,et al.  The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes , 1997, Surgery Today.

[23]  Phillip I. Good,et al.  Resampling Methods: A Practical Guide to Data Analysis , 2005 .

[24]  Bjørn Naume,et al.  Circulating and disseminated tumor cells. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Tartter,et al.  Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. , 2005, Journal of the American College of Surgeons.

[26]  Antoine Flahault,et al.  An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement , 2005, Breast Cancer Research and Treatment.

[27]  Malcolm Pradhan,et al.  A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. , 2004, Breast.

[28]  G. Vlastos,et al.  Ratios of involved nodes in early breast cancer , 2004, Breast Cancer Research.

[29]  A. Fortin,et al.  The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Vanessa Didelez,et al.  Survival Analysis Using S. Analysis of Time-to-Event Data , 2004 .

[31]  R. Newcombe,et al.  Predictors of non-sentinel lymph node metastasis in breast cancer patients. , 2004, European journal of cancer.

[32]  Peter C Austin,et al.  Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses , 2004, Statistics in medicine.

[33]  G. Storme,et al.  The lymph node ratio as prognostic factor in node-positive breast cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  E. Ross,et al.  The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2004, The American surgeon.

[35]  G. Boross,et al.  Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. , 2004, Japanese journal of clinical oncology.

[36]  H. Herr Superiority of ratio based lymph node staging for bladder cancer. , 2003, The Journal of urology.

[37]  G. Storme,et al.  Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. , 2003, International journal of oncology.

[38]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[39]  F. Vicini,et al.  Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. , 2002, International journal of radiation oncology, biology, physics.

[40]  F. Yıldız,et al.  T3N0M0 Breast cancer patients: A subgroup with favorable prognosis , 2003 .

[41]  0 M 0 Breast cancer patients : A subgroup with favorable prognosis , 2003 .

[42]  Menggang Yu,et al.  Bias and efficiency loss due to categorizing an explanatory variable , 2002 .

[43]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Edge,et al.  AJCC Cancer Staging Handbook, 6th edition , 2002 .

[45]  S. Choi,et al.  Prognostic Significance of Metastatic Lymph Node Ratio in T3Gastric Cancer , 2002, World Journal of Surgery.

[46]  B. Rasmussen,et al.  Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Schumacher,et al.  On the Problem of Using ‘Optimal’ Cutpoints in the Assessment of Quantitative Prognostic Factors , 2001, Oncology Research and Treatment.

[48]  Yogendra P. Chaubey,et al.  Resampling Methods: A Practical Guide to Data Analysis , 2000, Technometrics.

[49]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[50]  N. Pavlidis,et al.  Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and ≥10 Positive Axillary Lymph Nodes , 1998, Oncology.

[51]  J. Siewert,et al.  Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. , 1998, Annals of surgery.

[52]  K. Zedeler,et al.  Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .

[53]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M Schumacher,et al.  Effects of covariate omission and categorization when analysing randomized trials with the Cox model. , 1997, Statistics in medicine.

[55]  C. Hudis,et al.  Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. , 1995, Seminars in oncology.

[56]  W. Farrar,et al.  The natural history of breast cancer with more than 10 positive nodes. , 1995, American journal of surgery.

[57]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[58]  Robert M. Elashoff,et al.  Effect of Categorizing a Continuous Covariate on the Comparison of Survival Time , 1986 .

[59]  Gail Gong Cross-Validation, the Jackknife, and the Bootstrap: Excess Error Estimation in Forward Logistic Regression , 1986 .

[60]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.